D

    DVAX (DVAX)

    Official site

    DRUG MANUFACTURERS - SPECIALTY & GENERIC

    $15.50
    +0.00 (+0.00%)

    Last updated: Feb 11, 2026 at 4:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    58%(22/38)
    Avg Surprise
    +24.56%

    Upcoming Estimates

    Mar 31, 2026
    EPS Consensus$-0.02
    Range$-0.02 - $-0.02
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.06-200.0%
    60d ago$-0.06-200.0%
    30d ago$-0.02+0.0%
    7d ago$-0.02+0.0%
    Current$-0.02
    Revenue Consensus
    $0
    Range$0 - $0
    0 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Mar 26EST
    		-$-0.02---
    Dec 25
    		$0.00N/A-100.00%Miss-100.0%
    Sep 25
    		$0.21$0.13+61.54%Beat+75.0%
    Jun 25
    		$0.14$0.10+40.00%Beat+75.0%
    Mar 25
    		$-0.01$0.01-173.98%Miss+87.0%
    Dec 24
    		$0.05$0.04+25.00%Beat+3025.0%
    Sep 24
    		$0.12$0.11+9.09%Beat+20.0%
    Jun 24
    		$0.08$0.06+33.33%Beat+166.7%
    Mar 24
    		$-0.07$-0.02-250.00%Miss+63.2%
    Dec 23
    		$0.00N/A+116.00%Beat-99.6%
    Sep 23
    		$0.10$-0.01+1100.00%Beat-76.7%
    Jun 23
    		$0.03N/A+133.33%Beat-96.6%
    Mar 23
    		$-0.19$-0.13-46.15%Miss-186.4%
    Dec 22
    		$0.45$0.43+4.65%Beat-18.2%
    Sep 22
    		$0.43$0.33+30.30%Beat+279.2%
    Jun 22
    		$0.87$0.22+295.45%Beat+4250.0%
    Mar 22
    		$0.22$0.24-8.33%Miss+2100.0%
    Dec 21
    		$0.55$0.64-14.06%Miss+492.9%
    Sep 21
    		$-0.24$0.05-580.00%Miss-1100.0%
    Jun 21
    		$0.02$-0.04+150.00%Beat+103.8%
    Mar 21
    		$0.01$-0.02+150.00%Beat+106.7%
    Dec 20
    		$-0.14$-0.24+41.67%Beat+68.2%
    Sep 20
    		$-0.02N/A+90.00%Beat+96.0%
    Jun 20
    		$-0.53$-0.24-120.83%Miss-1.9%
    Mar 20
    		$-0.15N/A+51.61%Beat+75.8%
    Dec 19
    		$-0.44$-0.33-33.33%Miss+31.3%
    Sep 19
    		$-0.50$-0.39-28.21%Miss+23.1%
    Jun 19
    		$-0.52$-0.56+7.14%Beat+17.5%
    Mar 19
    		$-0.62$-0.65+4.62%Beat+1.6%
    Dec 18
    		$-0.64$-0.61-4.92%Miss-48.8%
    Sep 18
    		$-0.65$-0.57-14.04%Miss-71.1%
    Jun 18
    		$-0.63$-0.63+0.00%Beat-53.7%
    Mar 18
    		$-0.63$-0.49-28.57%Miss-5.0%
    Dec 17
    		$-0.43$-0.33-30.30%Miss+23.2%
    Sep 17
    		$-0.38$-0.47+19.15%Beat+57.8%
    Jun 17
    		$-0.41$-0.44+6.82%Beat-
    Mar 17
    		$-0.60$-0.51-17.65%Miss-
    Dec 16
    		$-0.56$-0.85+34.12%Beat-
    Sep 16
    		$-0.90$-0.75-20.00%Miss-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$15.49
    SMA 20$15.54
    SMA 50$13.94
    SMA 200$11.26
    EMA 10$15.50
    EMA 20$15.34
    EMA 50$14.25
    EMA 200$12.29

    MACD

    Line: 0.34Signal: 0.47Hist: -0.13

    ADX

    ADX: 59.7+DI: 46.8-DI: 12.4

    Aroon & PSAR

    Aroon Up16.0
    Aroon DownN/A
    PSAR$13.98

    Bollinger Bands

    Upper Band$15.68
    Lower Band$15.39
    %B Position187%(Upper)
    Band Width0.36

    RSI (14-Day)

    Overbought
    76.0

    Momentum Oscillators

    Stoch %K14.6
    Stoch %D13.5
    Williams %R-83.3
    ROC (10d)0.1%
    Momentum0.02
    CCI (20d)-48.1
    MFI (14d)22.5

    Volatility Measures

    ATR (14d)$0.10(0.6%)
    StdDev (20d)0.07
    Hist Vol4.6%(Low)

    Volume Flow

    VWAP$15.50
    OBV57.1M
    AD Line-63.2M
    CMF (20d)-0.091

    Volume Metrics

    Avg Vol (20d)2.3M
    Vol RatioN/A
    VWMA (20d)$15.54

    Pivot Points

    R3$15.50
    R2$15.50
    R1$15.50
    Pivot Point$15.50
    S1$15.50
    S2$15.50
    S3$15.50

    Advanced Oscillators

    TSI57.28
    Ultimate Osc36.1
    KST134.64

    Financial Data

    QuarterSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total Revenue$94.88M$95.44M$68.16M$72.03M$80.63M$73.80M$50.79M$55.60M$69.51M$60.25M$46.92M$184.49M
    Cost of Revenue$14.40M$14.04M$13.77M$13.41M$13.08M$11.98M$10.97M$8.69M$13.23M$13.54M$14.71M$77.49M
    Gross Profit$80.47M$81.41M$54.40M$58.62M$67.55M$61.81M$39.82M$46.91M$56.28M$46.71M$32.21M$107.00M
    Operating Expenses$59.20M$66.98M$78.03M$60.25M$57.46M$56.61M$57.59M$55.40M$51.17M$50.12M$62.46M$43.87M
    R&D$19.12M$16.62M$19.38M$18.67M$14.40M$14.95M$13.53M$14.12M$14.12M$13.05M$13.61M$12.85M
    SG&A$40.09M$50.36M$47.68M$41.59M$43.06M$41.66M$44.06M$41.28M$38.05M$37.07M$36.54M$31.02M
    Operating Income$21.27M$14.43M$-23,630,000$-1,633,000$10.08M$5.20M$-17,769,000$-8,491,000$5.12M$-3,405,000$-30,248,000$63.13M
    Interest Income$6.59M$9.02M$7.74M$13.43M$9.38M$9.20M$9.47M$17.13M$8.46M$7.38M$6.60M$6.35M
    Interest Expense$1.64M$1.64M$83.79M$1.70M$1.70M$1.70M$1.70M$1.69M$1.69M$1.69M$1.69M$1.68M
    Income Before Tax$28.42M$21.22M$-97,875,000$7.63M$19.82M$14.91M$-11,497,000$996,000$14.15M$4.21M$-23,716,000$67.97M
    Income Tax Expense$1.49M$2.50M$-1,776,000$578,000$2.22M$3.52M$-2,776,000$777,000$-147,000$776,000$616,000$241,000
    Net Income$26.93M$18.72M$-96,099,000$7.05M$17.59M$11.39M$-8,721,000$219,000$14.29M$3.43M$-24,332,000$67.73M
    EBITDA$24.39M$14.17M$-21,928,000$-4,831,000$10.91M$5.45M$-21,850,000$-17,729,000$5.20M$-3,455,000$-30,470,000$62.27M
    EBIT$23.50M$13.83M$-21,827,000$-4,249,000$12.29M$7.40M$-19,270,000$-14,445,000$7.38M$-1,483,000$-28,627,000$63.03M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DVAX

    News

    DVAX6344162 Bond Profile — Key Metrics

    This article provides key metrics for the Dynavax Technologies Corporation bond, DVAX6344162. It details the bond's coupon rate, maturity date, issue date, and face value. The article also includes a brief profile of Dynavax Technologies Corp., highlighting its focus on biopharmaceuticals and its main product, HEPLISAV-B.

    TradingView•7/21/26•
    Neutral

    Dynavax Technologies points to vaccine revenue potential. U.S. listing supports investor interest

    Dynavax Technologies, a biopharmaceutical company listed on Nasdaq, focuses on developing and commercializing vaccines and immunology products, primarily generating revenue through its adult hepatitis B vaccine and collaborations. The company's strategy involves leveraging proprietary immune-activating technologies to enhance vaccine effectiveness and expanding into new markets through partnerships. Its U.S. listing provides visibility and liquidity, with valuation reflecting future vaccine uptake and successful technology partnerships.

    AD HOC NEWS•7/9/26•
    Neutral

    Dynavax Technologies focuses on vaccine platforms as investors watch long-term growth

    Dynavax Technologies is expanding its vaccine and immunology platforms, aiming for durable revenue streams and long-term growth. The company specializes in adjuvanted vaccines for adult and high-risk populations, leveraging its proprietary TLR9 agonist technology to enhance immune responses. Its strategy involves diversifying revenue through new indications, partnerships, and market expansion, which are key for sustained investment in research and managing competitive pressures.

    AD HOC NEWS•7/7/26•
    Bullish

    Dynavax Technologies Corp (DVAX) Financial Health: Profitability & Balance Sheet Analysis

    Dynavax Technologies Corp (DVAX) shows strong financial health, with its latest quarterly revenue climbing 17.67% year-over-year to $94.88 million and net profit increasing by 53.05%. The company's financial scores indicate excellent operational efficiency and growth potential, achieving perfect scores in these categories. While specific data for certain metrics are still undisclosed, the overall financial health score is 8.07, demonstrating a robust performance.

    TradingKey•6/18/26•
    Bullish

    Dynavax Technologies Corp (DVAX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

    This article provides a technical analysis of Dynavax Technologies Corp (DVAX), focusing on its current price momentum, support and resistance levels, and key technical indicators. It notes that DVAX's current price momentum is ranked 327 out of 391 in its industry, trading between a resistance level of $15.67 and a support level of $15.40. The analysis concludes with a "Buy" signal based on moving averages and other technical indicators.

    TradingKey•6/17/26•
    Neutral

    Frequently Asked Questions About DVAX

    Does DVAX pay dividends?
    DVAX (DVAX) does not currently pay a regular dividend.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In